OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and vascular anomalies. The company utilizes a structure-based drug design platform to develop small molecule drugs that selectively target specific mutations while sparing wild-type proteins. Its lead product candidate, OKI-219, is a highly selective inhibitor of the PI3Kα H1047R mutation, currently being investigated in the Phase 1 PIKture-01 clinical trial for patients with advanced breast cancer and other solid tumors. The company is also pursuing additional discovery programs targeting other common PI3Kα mutations, such as E545K and E542K, as well as a program in vascular malformations. OnKure develops therapies designed to minimize on-target toxicities associated with non-selective inhibition of wild-type PI3Kα.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage onkuretherapeutics.com
Sector Healthcare IR page investors.onkuretherapeutics.com
Tags
precision medicine, oncology, small molecule drugs, pi3kα inhibitors, breast cancer, vascular anomalies, structure-based drug design, clinical-stage, OKI-219, PIKture-01
Press page —

Metrics

Valuation  
Market cap $ 110.371M
Market cap (USD) $ 110.371M
P/E -0.99
PEG —
P/BV 0.70
P/S —
P/OCF -2.30
P/FCF -2.30
Dividend yield —
Turnover / mcap —
Returns  
ROE -74.4%
ROI -105.9%
ROIC -84.0%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -63.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Assets 62.117M 114.907M
Net profit -59.517M -52.673M
Free cash flow -51.874M -51.169M

Figure FY 2025 FY 2024
Share price 2.9 8.6
Price performance 12m -0.66 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 1.46M 973,000 1.09M 549,000
Cash and deposits (USD) 17.5M 53.6M 125M 19.9M 27.6M 111M 59.1M
Right-of-use assets (USD) — — — 1.29M 599,000 770,000 387,000
Cash flow detail
Operating cash flow (USD) — -18.5M -38M -47.4M -63.7M -51.1M -51.8M
Purchases of property, plant and equipment (USD) — -24,000 -198,000 -346,000 -221,000 -52,000 -46,000
Change in payables (cash effect) (USD) — 1.49M 1.78M 518,000 11.1M -5.93M -4.55M
Share buybacks (cash effect) (USD) — — — — -4.4M — —
Income taxes paid (cash effect) (USD) — — — — — 0.00 0.00
Share-based compensation (USD) — 393,000 3.89M 4.32M 5.11M 4.53M 11.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -18.6M -38.2M -47.7M -63.9M -51.2M -51.9M
Income detail
Research and development expense (USD) — 15.9M 28.2M 37.7M 56.6M 43.8M 48.3M
↳ 5y CAGR +24.8%
Total comprehensive income (USD) — -19.5M -39.7M -52M -77.3M — —
Comprehensive income to owners (USD) — -19.5M -39.7M -52M -77.3M — —
Reported May 20, 2021 Mar 23, 2022 Mar 23, 2022 Mar 27, 2023 Mar 28, 2024 Mar 12, 2026 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies

-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant-selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027

BOULDER, CO, November 4, 2026 -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the third quarter ended September 30, 2026, and provided recent business highlights.

“We continue to advance the development of next-generation PI3Kα pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027,” said Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure.

August 31, 2026

PDF Version

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.

The OnKure management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to schedule meetings.

About OnKure Therapeutics

OnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of vascular anomalies and cancers that are underserved by available therapies. Using a structure and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of vascular anomalies and cancer. OnKure aims to become a leader in targeting PI3Kα and has multiple programs designed to enable best-in-class targeting of this important molecular target.

(e) Repricing of Certain Underwater Options

On August 7, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of OnKure Therapeutics, Inc. (the “Company”) approved an option repricing. The repricing generally applied to all outstanding and unexercised stock options to purchase shares of the Company’s Class A common stock (“Shares”) granted prior to January 1, 2025, under the Company’s 2024 Equity Incentive Plan or the Company’s 2021 Stock Incentive Plan (each, a “Plan”), with an exercise price per Share equal to or greater than $10.00, held by certain employees and consultants (such options, the “Eligible Options”), including each of the Company’s named executive officers, as of the Effective Date.

The options held by the Company’s named executive officers that were repriced included Eligible Options covering an aggregate of 571,423 Shares held by Nicholas A.

Prompts

OnKure Therapeutics, Inc. (ticker OKUR), listed in United States.

Company History

Date Change Detail
Jul 18, 2024 Renamed RENEO PHARMACEUTICALS, INC. → ONKURE THERAPEUTICS, INC.
— Former tickers RPHM

ETFs Holding OnKure Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
TMED 0.30% 15,335 $ 69.928K Jun 30, 2026
DFAS 0.00% 35,233 $ 106.051K Nov 12, 2026
DCOR 0.00% 3,580 $ 10.776K Nov 12, 2026
AVSC 0.00% 30,625 $ 84.219K Nov 16, 2026